phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体-抗体-抗体-生物在线
phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体

phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体

商家询价

产品名称: phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体

英文名称: Anti-phospho-ECT2 (Ser370) antibody

产品编号: HZ-10317R

产品价格: null

产品产地: 中国/美国

品牌商标: HZbscience

更新时间: 2023-08-17T10:24:20

使用范围: WB,ELISA,IHC-P,IHC-F,IF

上海沪震实业有限公司
  • 联系人 : 鲍丽雯
  • 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
  • 邮编 : 200612
  • 所在区域 : 上海
  • 电话 : 139****0749
  • 传真 : 021-60345367
  • 邮箱 : www.shzbio.net

phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体

产品编号HZ-10317R
英文名称phospho-ECT2 (Ser370)
中文名称磷酸化上皮细胞癌转化蛋白2抗体
别 名ECT2 (phospho S370); ECT2 (phospho Ser370); p-ECT2 (Ser370); ECT 2; ECT2; ECT-2; ECT2 protein; Epithelial cell transforming sequence 2; Epithelial cell transforming sequence 2 oncogene; Epithelial cell transforming sequence 2 oncogene protein; FLJ10461; MGC138291; Protein ECT2; ECT2_HUMAN; Epithelial cell-transforming sequence 2 oncogene.
说 明 书0.1ml
产品类型磷酸化抗体
研究领域
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 Human,
phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体产品应用WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human ECT2 around the phosphorylation site of Ser370
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体PubMedPubMed
产品介绍background:
The protein encoded by this gene is a transforming protein that is related to Rho-specific exchange factors and yeast cell cycle regulators. The expression of this gene is elevated with the onset of DNA synthesis and remains elevated during G2 and M phases. In situ hybridization analysis showed that expression is at a high level in cells undergoing mitosis in regenerating liver. Thus, this protein is expressed in a cell cycle-dependent manner during liver regeneration, and is thought to have an important role in the regulation of cytokinesis. [provided by RefSeq].

Function:
Guanine nucleotide exchange factor (GEF) that catalyzes the exchange of GDP for GTP. Promotes guanine nucleotide exchange on the Rho family members of small GTPases, like RHOA, RHOC, RAC1 and CDC42. Required for signal transduction pathways involved in the regulation of cytokinesis. Component of the centralspindlin complex that serves as a microtubule-dependent and Rho-mediated signaling required for the myosin contractile ring formation during the cell cycle cytokinesis. Regulates the translocation of RHOA from the central spindle to the equatorial region. Plays a role in the control of mitotic spindle assembly; regulates the activation of CDC42 in metaphase for the process of spindle fibers attachment to kinetochores before chromosome congression. Involved in the regulation of epithelial cell polarity; participates in the formation of epithelial tight junctions in a polarity complex PARD3-PARD6-protein kinase PRKCQ-dependent manner. Plays a role in the regulation of neurite outgrowth. Inhibits Phenobarbital (PB)-induced NR1I3 nuclear translocation. Stimulates the activity of RAC1 through its association with the oncogenic PARD6A-PRKCI complex in cancer cells, thereby acting to coordinately drive tumor cell proliferation and invasion. Also stimulates genotoxic stress-induced RHOB activity in breast cancer cells leading to their cell death.

phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体Subunit:
Interacts with NR1I3 (By similarity). Homodimer. Homooligomer. Found in the centralspindlin complex. Interacts (Thr-359 phosphorylated form) with PARD6A; the interaction is observed in cancer cells. Interacts (Thr-359 phosphorylated form) with PRKCI; the interaction is observed in cancer cells. Interacts with PKP4; the interaction is observed at the midbody. Interacts with RACGAP1; the interaction is direct, occurs in a microtubule-dependent manner, is inhibited in metaphase by phosphorylation of ECT2 on Thr-373 and is stimulated in early anaphase by dephosphorylation of ECT2 probably on Thr-373 through CDK1 activity. Interacts with PLK1; the interaction is stimulated upon its phosphorylation on Thr-444. Associates with RACGAP1 at anaphase and during cytokinesis. Interacts with KIF23, PARD3, PARD6A, PARD6B and PRKCQ.

Subcellular Location:
Nucleus. Cytoplasm. Cytoplasm, cytoskeleton, spindle. Cleavage furrow. Midbody. Cell junction. Cell junction, tight junction. Note=Sequestered within the nucleus during interphase. Dispersed throughout the cytoplasm upon breakdown of the nuclear envelope during mitosis. Colocalizes with the centralspindlin complex to the mitotic spindles during anaphase/metaphase, the cleavage furrow during telophase and at the midbody at the end of cytokinesis. Colocalized with RhoA at the midbody. Its subcellular localization to tight junction is increased by calcium. Localized predominantly in the cytoplasm of numerous carcinoma cells.

Tissue Specificity:
Expressed in lung epithelial cells (at protein level). Expressed in squamous cell carcinoma, primary non-small cell lung cancer tumors and lung adenocarcinoma. [INDUCTION] Up-regulated by calcium in cells forming cell-cell contact sites. Up-regulated by DNA damaging agents like H(2)O(2) or ionizing radiation (IR).

Post-translational modifications:
Phosphorylated by PLK1 in vitro. Hyperphosphorylated during the G2 phase of the cell cycle. Phosphorylation at Thr-373 occurs during the G2/M phase, relieves its auto-inhibition status and stimulates its GEF activity. Phosphorylation at Thr-444 in G2/M phase is required for subsequent binding with PLK1 and Rho exchange activation. Dephosphorylated at the time of cytokinesis. Phosphorylation at Thr-359 is required for its transformation activity in cancer cells.

DISEASE:

phospho-ECT2 (Ser370),磷酸化上皮细胞癌转化蛋白2抗体Similarity:
Contains 2 BRCT domains.
Contains 1 DH (DBL-homology) domain.
Contains 1 PH domain.

Database links:
UniProtKB/Swiss-Prot: Q9H8V3.4

Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.